Efficacy and Safety of Ibrutinib in Patients With CLL and Other Indolent B-cell Lymphomas Who Are Chronic Hepatitis B Virus Carriers or Occult Hepatitis B Virus Carriers
Efficacy and Safety of Ibrutinib in Patients With CLL and Other Indolent B-cell Lymphomas Who Are Chronic Hepatitis B Virus Carriers or Occult Hepatitis B Virus Carriers
Efficacy and Safety of ibrutinib in patients with chronic lymphocytic leukemia and other
 indolent B-cell lymphomas who are chronic hepatitis B virus carriers or occult hepatitis B
 virus carriers
Ibrutinib is a selective oral Burton tyrosine kinase inhibitor. Through interfering with the
 downstream pathways of B-cell receptor signaling, it inhibits proliferation and induces
 apoptosis in many B-cell lymphoid malignancies. The clinical benefit of ibrutinib has been
 demonstrated in patients with relapsed/refractory chronic lymphocytic leukaemia, mantle cell
 lymphoma, small lymphocytic lymphoma, and other indolent B-cell non-Hodgkin lymphomas.

 The pivotal trials of ibrutinib excluded HBsAg+ patients. Therefore, the effects of ibrutinib
 on HBsAg+ and anti-HBc+ patients remain entirely undefined. In view of the B-cell signaling
 inhibitory activity of ibrutinib, which might be more potent than rituximab in suppressing
 B-cells, HBV reactivation in patients exposed previously to HBV infection, including chronic
 HBV carriers and occult HBV carriers, could be a major clinical problem.

 To enable ibrutinib to be prescribed in Asia and other regions of the world where HBV is
 endemic, evidence-based recommendations on prevention of HBV reactivation in at-risk
 populations, including chronic HBV carriers (HBsAg+), and occult HBV carriers (HBsAg- but
 anti-HBc+), are urgently needed.

 The following treatment regimens will be adopted. Relapsed / refractory chronic lymphocytic
 leukemia and Waldenstrom macroglobulinaemia (lymphoplasmacytic lymphoma): 420 mg daily.

 Relapsed / refractory mantle cell lymphoma: 560 mg daily. Relapsed / refractory indolent
 B-cell non-Hodgkin lymphoma: 560 mg daily. Treatment is continued until disease progression.

 A total of 62 patients will be recruited, including 16 HBsAg+ patients, and 46 occult HBV
 carriers

 Sample size calculation of occult HBV carriers For occult HBV carriers, the sample size is
 calculated according to the following information, based on our previous observations (as
 detailed in reference 3). The HBV reactivation rate in HBsAg-, anti-HBc+, anti-HBs+ patients
 is hypothesized to be 34%, which may increase to 68% in HBsAg-, anti-HBc+, but anti-HBs-
 patients [3]. Assuming a power of 80% and an alpha-risk of 0.1, together with the ratio of
 anti-HBs+ : anti-HBs- patients to be 2:1, we expect to recruit 42 HBsAg-, anti-HBc+ patients.
 With a dropout rate of 10%, the total number of patients to be recruited in this group will
 be 46.

 Sample size calculation of HBsAg+ patients For HBsAg+ patients, the sample size is calculated
 according to the following information, based on our previous observations (as detailed in
 reference 3). The ratio of occult carriers (HBsAg-, anti-HBc+) : HBsAg+ patients is about 3:
 1.3 Hence, the total number of HBsAg+ to be recruited will be 14 (42 divided by 3). With a
 drop-out rate of 10%, the total number of patients to be recruited in this group will be 16.

 Approximate breakdown of number of patients in each category to be recruited Based on our
 previous observations on the proportions of low-grade B-cell lymphoid malignancies,8 an
 approximate breakdown of number of patients is as follows: follicular lymphoma (N=32),
 chronic lymphocytic leukemia/small lymphocytic lymphoma (N=11), marginal zone B-cell lymphoma
 (N=11), mantle cell lymphoma (N=5), and Waldenstrom macroglobulinemia (N=5).
Inclusion Criteria:

 1. Adult patients between age of 18 - 80 years

 2. Patients with indolent B-cell lymphoproliferative neoplasms that have relapsed or are
 refractory after at least one standard line of therapy that contains rituximab

 3. Pathologically proven B-cell lymphoproliferative neoplasms including chronic
 lymphocytic leukaemia/small lymphocytic lymphoma, mantle cell lymphoma, marginal-zone
 B-cell lymphoma, and Waldenstrom macroglobulinaemia (lymphoplasmacytic lymphoma).

 4. Pathologically proven follicular lymphoma, with relapse or disease progression > 12
 months after previous rituximab therapy.

 5. Chronic HBV carriers (HBsAg+)

 6. Occult HBV carriers (HBsAg-, anti-HBc+ and HBV DNA-)

 7. Haematology values within the following limits:

 1. Absolute neutrophil count (ANC)1000/mm3 independent of growth factor support

 2. Platelets 100,000/mm3, or 50,000/mm3 if bone marrow is involved, and independent
 of transfusion support in either situation

 8. Biochemical values within the following limits:

 1. Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 2 x upper
 limit of normal (ULN)

 2. Total bilirubin ≤ 1.5 x ULN unless bilirubin rise is due to Gilbert's syndrome or
 of non-hepatic origin

 3. Serum creatinine ≤ 2 x ULN or estimated Glomerular Filtration Rate (Cockcroft
 Gault) ≥ 40 mL/min/1.73m2

 9. Competent to give an informed consent

 Exclusion Criteria:

 1. Concomitant chronic liver diseases not related to HBV

 2. Known history of drug-induced liver injury, chronic active hepatitis C infection,
 alcoholic liver disease, non-alcoholic steatohepatitis, primary biliary cirrhosis,
 on-going extra-hepatic obstruction caused by cholelithiasis, cirrhosis of the liver
 and portal hypertension

 3. Known history of drug induced pneumonitis

 4. Known history of inflammatory bowel disease

 5. Woman who are pregnant or breast-feeding

 6. Patients who do not consent to the use of effective contraception during the study

 7. Active infections.

 8. Evidence of ongoing active HBV hepatitis (ALT and/or AST > 2x upper limit of normal,
 and detectable HBV DNA)

 9. Patients known to have histological transformation of CLL to an aggressive lymphoma

 10. Vaccinated with live, attenuated vaccines within 4 weeks of enrolment